RxDoctor Payments Data

Michael Trimba, MD

Interventional Pain Medicine · Brooklyn, NYNPI 1396725081

Payments from drug & device makers

$3,203in general payments, 2019–2025

Across 162 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$390
  • Fidia Pharma USA Inc.$337
  • Pacira Therapeutics, Inc.$328
  • Arbor Pharmaceuticals, Inc.$316
  • Scilex Pharmaceuticals Inc.$301
  • Amgen$272
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,18299%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,203 in reported general payments places this provider in the 40th percentile of 132 interventional pain medicine providers in New York.

See all interventional pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$463,596
Medicare patients
480
Services billed
7,182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium88$30,898
ZtlidoLidocaine63$21,418
LyricaPregabalin11$9,657
HorizantGabapentin Enacarbil20$9,391
Doxepin Hcl20$4,014
Diclofenac Sodium ErDiclofenac Sodium35$3,102
Oxycodone Hcl131$2,633
Naproxen Sodium21$2,171
Acetaminophen-CodeineAcetaminophen With Codeine117$1,762
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen106$1,646
Lidocaine18$1,499
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen53$1,053
Morphine Sulfate ErMorphine Sulfate32$745
Tramadol Hcl96$742
Pregabalin19$681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Ztlido$301$21,41863 claims
PfizerLyrica$59$9,65711 claims
Arbor Pharmaceuticals, Inc.Horizant$316$9,39120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 132 interventional pain medicine providers in New York.

Other interventional pain medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →